Physician profile
Steven Schechter
NPI 1740241876
$45,155.93
in general payments reported to CMS, 2019-2025
12 companies · $37K in 2025
The $37K reported for 2025 was more than what 98% of Colon & Rectal Surgery providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $183 · 2021: $562 · 2022: $317 · 2023: $3,006 · 2024: $4,095 · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $43K · Food and Beverage: $551 · Consulting Fee: $435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $42,954.09 |
| Food and Beverage | $551.17 |
| Consulting Fee | $435.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $43,830.86 | 2022-2025 | Phasix Mesh, Ventralight St |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $500.00 | 2021 | |
| Mdd US Operations, LLC | $336.57 | 2019-2020 | |
| Medtronic, INC. | $178.26 | 2023 | Sonicision, Ligasure, Signia |
| Pacira Pharmaceuticals Incorporated | $140.72 | 2024 | Exparel |
| Novartis Pharmaceuticals Corporation | $62.25 | 2021 | |
| Genentech USA, INC. | $25.67 | 2025 | Ocrevus Zunovo |
| Eisai INC. | $24.51 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $20.67 | 2024 | Nuedexta |
| Pfizer INC. | $19.08 | 2024 | |
| Tg Therapeutics, INC. | $17.34 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Schechter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.